全文获取类型
收费全文 | 160篇 |
免费 | 13篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 2篇 |
妇产科学 | 2篇 |
基础医学 | 13篇 |
口腔科学 | 1篇 |
临床医学 | 19篇 |
内科学 | 29篇 |
特种医学 | 1篇 |
外科学 | 5篇 |
综合类 | 35篇 |
预防医学 | 51篇 |
药学 | 11篇 |
肿瘤学 | 6篇 |
出版年
2021年 | 1篇 |
2019年 | 2篇 |
2017年 | 4篇 |
2016年 | 2篇 |
2015年 | 3篇 |
2014年 | 9篇 |
2013年 | 8篇 |
2012年 | 11篇 |
2011年 | 9篇 |
2010年 | 4篇 |
2009年 | 3篇 |
2008年 | 7篇 |
2007年 | 8篇 |
2006年 | 7篇 |
2005年 | 7篇 |
2004年 | 6篇 |
2003年 | 8篇 |
2002年 | 2篇 |
2001年 | 4篇 |
2000年 | 1篇 |
1999年 | 3篇 |
1998年 | 5篇 |
1997年 | 6篇 |
1996年 | 4篇 |
1995年 | 9篇 |
1994年 | 19篇 |
1993年 | 9篇 |
1992年 | 9篇 |
1991年 | 2篇 |
1990年 | 3篇 |
排序方式: 共有175条查询结果,搜索用时 15 毫秒
1.
杜国有 《中华流行病学杂志》1994,15(5):278-281
笔者应用ELISA法对广西百色地区179例各类肝病患者及41例受血者血清进行了抗-HCV检测。结果各类肝病抗-HCV阳性率为17.9%,受血者抗-HCV阳性率为31.7%。在急性肝炎(急肝)、慢性肝炎(慢肝)、肝硬化和肝癌中,抗-HCV阳性率各为4.3%(1/23)、12.8%(10/78)、28.6%(12/42)和25.0%(9/36)。抗-HCV阳性率有随肝病慢性比而增高的趋势,肝硬化的抗-HCV阳性率明显高于急肝或慢肝(P<0.05),而肝癌的抗-HCV阳性率与急肝或慢肝相差不显著(P>0.05或0.1),且发现HBsAg阴性肝病者的抗-HCV阳性率明显高于HBsAg阳性患者(P<0.5),肝病患者抗-HCV的检出率与ALT活性无关(P>0.05)。在受血者中,抗-HCV的检出率与受血次数、ALT活性关系非常密切。因此,加强对HCV的检测是当前预防输血后肝炎的紧迫任务。 相似文献
2.
3.
目的:了解有偿和无偿献者HBsAg、抗-HCV、抗-HIV I/II测定结果。方法:均采用酶联吸附试验(ELISA)法。结果:有偿和无偿献血者之HBsAg阳性率分别为2.39%和3.32%,抗-HCV阳性率分别为4.81%和2.89%,抗-HIV I/II结果均为阴性。结论:有偿与无偿献血者之间的HBsAg和抗-HCV阳性率比较均有显著性差异(t值分别为2.8633和2.3638,P<0.05)。 相似文献
4.
5.
G. Sabatino L.A. Ramenghi M. di Marzio E. Pizzigallo 《European journal of epidemiology》1996,12(5):443-447
The risk of mother-to-infant transmission of hepatitis C virus (HCV) varies according to the population studied and the tests used. Aim of the current study was to investigate HCV vertical transmission rate in children born to 30 HCV positive/HIV negative pregnant women in Italy. We investigated the potential vertical transmission of HCV by identifying HCV antibody seropositive pregnant women, by analyzing HCV-RNA in the peripheral blood using PCR and by prospectively following their offspring until 24 months of age. During the third trimester, 2,980 consecutive pregnant women were examined for anti-HCV antibodies by a second generation Enzyme-Linked Immunosorbent Assay (EIA2) and re-assayed by a second generation Recombinant Immunoblot Assay (RIBA2). A total of 32 mothers (1.07%) were positive for EIA2 test; 30 out of 32 had a reactive confirmatory RIBA2 test for HCV All anti-HCV positive mothers were negative for HIV. These 30 mothers and their 30 babies formed the study cohort. Of the 30 anti-HCV positive mothers, 10 were also positive for serum HCV-RNA by PCR. All the babies born to the 30 anti-HCV positive mothers were initially negative for HCV-RNA (cord blood specimens), but three babies became positive at three months of age and remained positive thereafter. These babies had been born to 3 of the 10 mothers with viremia during the third trimester of pregnancy. These results suggest that HCV vertical transmission is possible in 10% of anti-HCV positives and in about 33% of the HCV-RNA seropositive mothers. 相似文献
6.
本文用分子生物学方法根据中国人HCV基因特点进行多肽合成,研究丙型肝炎C区、E区酶标试剂的临床应用以及与抗C 100-3试剂的比较,并以 RT双 PCR的方法建立了HCV RNA的检测试剂及临床应用。结果发现抗-CP试剂敏感性、特异性均优于抗C100-3,从临床检测结果看,在自然人群中感染率抗-CP为2.8%,抗C100-3为2.1%,特别在输血后肝炎中,抗 CP阳性率高达 71.7%~75.9%。因此提出对HCV的诊断确立与愈后判断各类试剂有各自的作用,不能只根据某一试剂的某一次结果而简单地否定 HCV感染。HCV RNA测定,建立了5’末端非编码区及非结构区(NS 1),采用双PCR观察结果抗-CP阳性者绝大多数为RNA阳性,并提示将有助于抗病毒药物疗效的观察指标。 相似文献
7.
Flavia Bortolotti MD Massimo Resti MD Raffaella Giacchino MD Chiara Azzari MD Nadia Gussetti MD Carlo Crivellaro MD Cristiana Barbera MD Francesco Mannelli MD Lucia Zancan MD Adalberto Bertolini MD 《The Journal of pediatrics》1997,130(6):990-993
Objective: To evaluate the clinical, biochemical, and virologic features associated with hepatitis C virus (HCV) infection acquired early in life from mothers with antibodies to HCV (anti-HCV).Study design: Multicenter prospective-retrospective study in Italian children.Patients: Two groups of children were investigated. Group 1 included 14 infants, born to mothers with anti-HCV but without human immunodeficiency virus infection, who became seropositive for HCV RNA during the first year of life and were thus considered infected. Group 2 included 16 children with chronic hepatitis C, aged 1
½ to 14 years, whose mothers were the unique potential source of infection. Both groups were followed for 12 to 48 months.Methods: Alanine transaminase (ALT), anti-HCV, and HCV RNA were investigated by the polymerase chain reaction on entry to the study and during follow-up.Results: All children in group 1 had anti-HCV throughout follow-up, and all had ALT abnormalities, ranging from 1.5 to 10.5 times the normal value during the first 12 months. During further follow-up, 5 of 10 children had HCV RNA with abnormal ALT values, 3 had a return to normal of the ALT values but continued to have viremia, and 2 eventually had normal ALT values and clearance of HCV RNA. Of the 16 children in group 2, all were free of symptoms and 62% had only slight ALT elevations; 7 who underwent liver biopsy had histologic features of minimal or moderate hepatitis.Conclusions: HCV infection acquired early in life from mothers with anti-HCV is usually associated with biochemical features of liver damage during the first 12 months of life. Progression to chronicity seems to occur in the majority of cases, although HCV-associated liver disease is likely to be mild throughout infancy and childhood. (J Pediatr 1997;130:990-3) 相似文献
8.
BackgroundScreening large numbers of persons in a population with low prevalence of a disease leads to many false-positives. However, populations with low HCV prevalence may sometimes be recommended for HCV screening, for instance patients or healthcare workers after a possible healthcare-related exposure.ObjectivesWe determined the percentage of true vs false-positive HCV antibody (anti-HCV) test results among 2007–2012 participants in the National Health and Nutrition Examination Study (NHANES), a nationally representative study with approximately 1% HCV infection prevalence, much lower than in groups typically recommended for HCV screening.Study designAnti-HCV test confirmation was performed using a recombinant immunoblot assay (RIBA) test and follow-up HCV RNA testing.ResultsOverall, of 22,359 NHANES participants tested, 479 (2%) were anti-HCV screening reactive and 477 were tested for RIBA; of these 323 (68%) confirmed as true positive and 105 (22%) were false-positives. Many others (49, 10%) were RIBA indeterminate and likely false-positive. Because of these false positive tests, the overall prevalence of chronic infection among those testing anti-HCV screening reactive was much lower (218, 51%) than would be expected due to disease clearance alone (approximately 80%).ConclusionsAll screening anti-HCV positive tests should be followed by an HCV RNA test, in order to confirm whether the patient has current infection so that infected persons can be referred to care and treatment to avoid the significant morbidity and mortality associated with chronic HCV infection. 相似文献
9.
《Critical reviews in microbiology》2013,39(4):535-547
AbstractChronic hepatitis C virus infection and associated liver diseases represent a major health care burden all over the world. The current standard of care, i.e. peginterferon-alfa (PEG-IFNα) plus ribavirin (RBV) are associated with frequent and sometimes serious adverse effects and contraindications, which further limit their therapeutic efficacy. The approval of first and second generation HCV protease inhibitors represents a major breakthrough in the development of novel direct acting antivirals (DAAs) against different HCV genotypes and establishes a new standard of care for chronically infected HCV genotypes 1 patients. Similarly, next generation protease inhibitors and HCV RNA polymerase inhibitors have shown better pharmacokinetics and pharmacodynamics in terms of broader HCV genotypes coverage, better safety profile, fewer drug interactions and possible once daily administration than first generation direct acting antivirals. The testing of adenovirus-based vector vaccines, which escalates the innate and acquired immune responses against the most conserved regions of the HCV genome in chimpanzees and humans, may be a promising therapeutic approach against HCV infection in coming future. This review article presents up-to-date knowledge and recent developments in HCV therapeutics, insights the shortcomings of current HCV therapies and key lessons from the therapeutic potential of improved anti-HCV treatment strategies. 相似文献
10.
162例丙型肝炎患者远期转归研究 总被引:1,自引:1,他引:1
目的观察162例不同临床感染类型丙型肝炎(HC)患者16年后的转归情况。方法将162例HC患者按急性期症状分组,采集5ml静脉血,检测丙型肝炎病毒(HCV)抗体、RNA、丙氨酸氨基转移酶(ALT)、透明质酸(HA)、Ⅲ型前胶原肽(PCⅢ)和Ⅳ型胶原(ⅣC)。结果本次调查的162例患者中抗-HCV阳性率为95.7%,HCVRNA阳性率为77.8%,ALT异常率为20.4%,不同临床类型HC患者抗-HCV、HCVRNA阳性率和ALT异常率间差异无统计学意义(P>0.05)。HA异常率为64.2%,PCⅢ异常率为9.3%,ⅣC异常率为40.1%。HA、PCⅢ和ⅣC3项指标均正常者共28例(18.52%),11例(6.8%)3项指标均处于肝硬化临界值。经性别分层分析,女性感染年龄≥40岁者抗体较易阴转(P=0.004)。结论不同临床型HC患者16年后的转归无差异,个体转归差异与性别和初始感染年龄有关。 相似文献